Adverum Biotechnologies
Adverum Biotechnologies is a clinical-stage company developing gene therapies for ocular diseases, with a focus on single-administration treatments like Ixo-vec for wet age-related macular degeneration.
Company Overview
Adverum Biotechnologies is a clinical-stage company dedicated to establishing gene therapy as a new standard of care for prevalent ocular diseases. The company focuses on developing durable, single-administration therapies that can be delivered in physicians’ offices, potentially eliminating the need for frequent ocular injections. Adverum Biotechnologies aims to transform the treatment landscape for debilitating ocular diseases, preserve vision, and generate a significant societal impact on a global scale.
Ixo-vec Gene Therapy
Adverum Biotechnologies' lead program, ixoberogene soroparvovec (Ixo-vec), is an innovative gene therapy candidate being developed as a one-time intravitreal injection for patients with neovascular or wet age-related macular degeneration (wet AMD). This therapy is designed to convert retinal cells into ocular biofactories that continuously produce therapeutic doses of aflibercept, a proven anti-VEGF treatment. Ixo-vec has the potential to extend treatment benefits from weeks to years, offering a significant improvement over the current standard of care.
OPTIC Clinical Program
The OPTIC clinical program by Adverum Biotechnologies is focused on investigating the safety and efficacy of Ixo-vec for treating wet AMD. The program evaluates patient outcomes over a two-year period post-treatment and assesses long-term effects for up to five years. The goal of OPTIC is to determine the potential of Ixo-vec to provide enduring benefits and to redefine the approach to managing wet AMD.
Environmental and Social Governance
Adverum Biotechnologies integrates environmental, social, and governance (ESG) objectives into its strategic decision-making. The company maintains a sustainability oversight program, with leadership dedicated to developing and monitoring sustainability initiatives and the board of directors providing ultimate oversight. Adverum sources electricity from Peninsula Clean Energy, ensuring its operations use 100% carbon-free energy. Additionally, the company actively works to reduce the environmental impact of its research and development activities.
Employee Benefits and Recognitions
Adverum Biotechnologies offers a competitive benefits package to support its pioneering team, including flexible work schedules, comprehensive health benefits, and competitive compensation. The 401(k) program includes dollar-for-dollar matching up to 3% of an employee's annual salary and an additional 50 cents per dollar for contributions on the next 2% of the salary. Adverum has been recognized as a 'Top Workplaces' by Bay Area News Group in 2021 and 2022, reflecting its commitment to fostering an excellent work environment.